이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Rafael Holdings 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

NYSE:RFL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
4/30/2024	1	-29	-6	-6	N/A
1/31/2024	0	2	-7	-7	N/A
10/31/2023	0	-2	-11	-11	N/A
7/31/2023	0	-8	-11	-11	N/A
4/30/2023	0	-14	-11	-11	N/A
1/31/2023	0	-18	-20	-20	N/A
10/31/2022	0	-16	-22	-22	N/A
7/31/2022	0	-123	-26	-26	N/A
4/30/2022	-2	-129	-31	-31	N/A
1/31/2022	-1	-127	-24	-24	N/A
10/31/2021	0	-133	-19	-19	N/A
7/31/2021	1	-23	-16	-16	N/A
4/30/2021	4	-18	-10	-10	N/A
1/31/2021	4	-17	-8	-8	N/A
10/31/2020	5	-10	-6	-6	N/A
7/31/2020	5	-10	-5	-5	N/A
4/30/2020	5	-7	-4	-4	N/A
1/31/2020	5	-6	-4	-4	N/A
10/31/2019	5	-6	-3	-3	N/A
7/31/2019	5	-5	-3	-3	N/A
4/30/2019	5	-4	-3	-3	N/A
1/31/2019	4	-3	-3	-3	N/A
10/31/2018	4	-3	-3	-3	N/A
7/31/2018	4	-12	-2	-2	N/A
4/30/2018	5	-10	-2	-2	N/A
1/31/2018	5	-10	N/A	-1	N/A
10/31/2017	5	-9	N/A	-1	N/A
7/31/2017	6	0	N/A	-2	N/A
7/31/2016	6	1	N/A	0	N/A
7/31/2015	4	0	N/A	-1	N/A

애널리스트 미래 성장 예측

수입 대 저축률: RFL 의 예상 수익 증가율이 절약률( 2.4% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: RFL 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: RFL 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: RFL 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: RFL 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: RFL 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Rafael Holdings 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New major risk - Financial position

Solid Earnings May Not Tell The Whole Story For Rafael Holdings (NYSE:RFL)

First half 2024 earnings released: EPS: US$0.10 (vs US$0.35 loss in 1H 2023)

Less than half of directors are independent

First quarter 2024 earnings released: US$0.15 loss per share (vs US$0.22 loss in 1Q 2023)

Rafael Holdings, Inc., Annual General Meeting, Jan 10, 2024

Full year 2023 earnings released: US$0.36 loss per share (vs US$6.21 loss in FY 2022)

Rafael Holdings, Inc. Announces Resignation of Rachel Jonas as Director

We Think Rafael Holdings (NYSE:RFL) Needs To Drive Business Growth Carefully

First half 2023 earnings released: US$0.35 loss per share (vs US$5.86 loss in 1H 2022)

Rafael Holdings, Inc. Announces Resignation of David Polinsky as Chief of Staff

First quarter 2023 earnings released: US$0.22 loss per share (vs US$5.88 loss in 1Q 2022)

Rafael Holdings GAAP EPS of -$0.22

Rafael Holdings, Inc., Annual General Meeting, Jan 23, 2023

Rafael stepping back from early-stage development in favor of acquisition, licensing

Founder & Chairman notifies of intention to sell stock

Rafael Holdings, Inc.(NYSE:RFL) dropped from Russell 2000 Dynamic Index

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.15 loss in 3Q 2021)

Rafael Holdings, Inc. Announces Directorate Changes

Is Rafael Holdings (NYSE:RFL) Using Debt In A Risky Way?

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of Cpi-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

First quarter 2022 earnings: Revenues in line with analyst expectations

Rafael Holdings: A Coin Flip

Full year 2021 earnings released: US$1.49 loss per share (vs US$0.66 loss in FY 2020)

Rafael Holdings, Inc. announced that it has received $104.169835 million in funding from a group of investors

Rafael Holdings, Inc. announced that it expects to receive $104.16987 million in funding

Rafael Holdings, Inc.(NYSE:RFL) dropped from Russell Microcap Value Index

Rafael Holdings announces merger with Rafael Pharmaceuticals

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 3Q 2020)

Rafael Holdings adds three new members to board

Second quarter 2021 earnings released

Rafael Holdings, Inc. Appoints Ameet Mallik as Chief Executive Officer, Effective May 1, 2021

New 90-day high: US$45.51

Rafael Holdings Names William Conkling as Chief Commercial Officer, Effective March 15, 2021

New 90-day high: US$28.00

What You Need To Know About Rafael Holdings, Inc.'s (NYSE:RFL) Investor Composition

New 90-day high: US$24.60

First quarter 2021 earnings released: US$0.091 loss per share

Rafael Holdings reports FQ1 results

New 90-day high: US$22.33

Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft

The Rafael Holdings (NYSE:RFL) Share Price Has Gained 29% And Shareholders Are Hoping For More

Rafael Holdings, Inc., Annual General Meeting, Jan 13, 2021

New 90-day high: US$21.65

Full year earnings released - US$0.66 loss per share

Rafael Holdings, Inc. to Report Q4, 2020 Results on Oct 29, 2020

New 90-day high - US$18.88

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견